Skip to Main Content

Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalot campus. There won’t be a newsletter this Thursday or Friday because of the Thanksgiving holiday. Speaking of which, if you wake up tomorrow and realize that your turkey hasn’t thawed, never fear, you can safely cook a fully or partially frozen turkey, according to the U.S. Department of Agriculture and my own experience; it just takes a little longer. With that public service announcement out of the way, here’s some news for you to peruse.

The European Patent Office has declared an mRNA patent owned by Moderna invalid, Reuters tells us. The announcement marks a win for Pfizer and BioNTech in their ongoing feud with Moderna over intellectual property at the heart of their Covid-19 vaccines. Moderna has said it disagrees with the decision and plans to file an appeal.

advertisement

Longtime drug industry ally Anna Eshoo plans to retire, STAT tells us. During her 30-plus years in Congress, she earned a reputation as an advocate for pharma-friendly policies, and one of her key achievements was adding a provision to the Affordable Care Act that ensures biologics have 12 years of market exclusivity. But she did vote to support the Inflation Reduction Act, which allows Medicare to negotiate the price of certain drugs.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.